Repligen Corporation (RGEN) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.

Total Cash From Operating Activities Chart for Repligen Corporation

Repligen Corporation (RGEN) operating cash flow for FY2025 was USD 117.4M, a -33.1% change from FY2024. Repligen Corporation's operating cash flow moved from USD -5.7M in 1990 to USD 117.4M in 2025 over 35 years. Operating cash flow compound annual growth rate: 5-year CAGR of 13.4%, 10-year CAGR of 22.8%, 20-year CAGR of 32.6%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$9.87B
Implied Share Price
$174.86
Enterprise Value
$10.29B
Revenue (TTM)
$785.10M
EBITDA
$144.10M
Profit Margin
5.29%
Trailing P/E
260.99
Forward P/E
67.11
Price/Book (MRQ)
4.93
Price/Sales (TTM)
12.57
EV/EBITDA
53.61
EV/Revenue
11.72
Dividend Yield
—
Book Value
$37.43
Free Cash Flow (FY2025)
$93.90M
Free Cash Flow Yield
0.95%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.